Last 33 quarters of trend data · Healthcare · Healthcare Software & Telehealth
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 31.07 | 19.68 | 21.20 | 14.64 | 45.86 | 35.87 | 28.95 | 32.85 | 35.94 | 38.09 | 42.07 | 56.10 | 71.50 | 53.16 | 65.57 | 44.61 | 228.37 | 71.27 | 82.53 | 258.55 | 83.92 |
| — | -45.1% | -26.8% | -55.4% | +27.6% | -5.8% | -31.2% | -41.4% | -49.7% | -28.3% | -35.8% | +25.8% | -68.7% | -25.4% | -20.6% | -82.7% | +172.1% | -13.5% | +6.3% | +248.5% | +208.8% | |
| P/S Ratio | 2.04 | 1.50 | 1.69 | 1.10 | 1.80 | 1.55 | 1.48 | 1.54 | 1.38 | 1.37 | 2.30 | 3.47 | 3.47 | 3.05 | 3.54 | 3.11 | 3.64 | 4.50 | 3.71 | 7.46 | 9.90 |
| — | -3.3% | +14.0% | -28.8% | +30.8% | +13.0% | -35.6% | -55.6% | -60.2% | -55.1% | -35.0% | +11.3% | -4.6% | -32.2% | -4.6% | -58.3% | -63.3% | -60.8% | -67.6% | -18.2% | -5.4% | |
| P/B Ratio | 6.04 | 4.94 | 5.22 | 3.28 | 4.45 | 3.47 | 3.83 | 4.27 | 3.90 | 3.62 | 6.14 | 6.74 | 6.77 | 6.66 | 8.43 | 7.58 | 8.27 | 10.67 | 9.31 | 18.37 | 20.06 |
| — | +42.4% | +36.4% | -23.3% | +14.1% | -4.1% | -37.6% | -36.7% | -42.4% | -45.7% | -27.2% | -11.0% | -18.1% | -37.6% | -9.4% | -58.7% | -58.8% | -57.5% | -67.7% | -23.9% | -20.2% | |
| P/FCF | 12.45 | 10.82 | 7.06 | 9.09 | 11.82 | 10.56 | 9.81 | 10.62 | 8.19 | 9.20 | 12.53 | 38.73 | 25.32 | 16.12 | 13.15 | 40.81 | 15.34 | 47.06 | 38.59 | — | 153.94 |
| — | +2.5% | -28.0% | -14.5% | +44.4% | +14.7% | -21.7% | -72.6% | -67.7% | -42.9% | -4.7% | -5.1% | +65.1% | -65.7% | -65.9% | — | -90.0% | -21.5% | — | — | -5.5% | |
| EV / EBITDA | 19.75 | 13.06 | 13.00 | 9.05 | 33.35 | 20.13 | 18.24 | 18.91 | 22.57 | 28.16 | 31.76 | 48.85 | 63.53 | 43.85 | 60.56 | 49.52 | 200.19 | 77.91 | 77.18 | 4170.80 | 9703.93 |
| — | -35.2% | -28.7% | -52.2% | +47.8% | -28.5% | -42.6% | -61.3% | -64.5% | -35.8% | -47.6% | -1.3% | -68.3% | -43.7% | -21.5% | -98.8% | -97.9% | -47.5% | -36.9% | +4501.2% | +1224.9% | |
| EV / EBIT | 31.01 | 13.38 | 13.63 | 9.04 | 30.99 | 19.15 | 17.22 | 18.01 | 21.29 | 20.84 | 27.17 | 41.74 | 66.45 | 45.24 | 62.66 | 51.30 | 227.20 | 80.71 | 80.55 | — | — |
| — | -30.1% | -20.9% | -49.8% | +45.6% | -8.1% | -36.6% | -56.9% | -68.0% | -53.9% | -56.6% | -18.6% | -70.8% | -43.9% | -22.2% | — | — | -47.1% | -35.8% | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 23.6% | 24.5% | 25.5% | 25.3% | 24.1% | 23.2% | 23.7% | 23.4% | 21.3% | 20.7% | 22.5% | 22.4% | 21.1% | 22.3% | 21.7% | 22.7% | 20.8% | 22.4% | 22.5% | 19.1% | 19.7% |
| — | +5.6% | +7.4% | +8.1% | +13.6% | +12.5% | +5.7% | +4.2% | +0.8% | -7.3% | +3.4% | -1.1% | +1.5% | -0.5% | -3.6% | +18.6% | +5.4% | -3.9% | -2.3% | -19.2% | -4.4% | |
| Operating Margin | 6.6% | 10.3% | 11.4% | 10.8% | 4.8% | 6.9% | 7.3% | 7.5% | 5.3% | 4.3% | 6.8% | 6.7% | 5.1% | 6.5% | 5.4% | 5.8% | 1.5% | 5.5% | 4.5% | -0.0% | -0.1% |
| — | +50.1% | +56.0% | +44.4% | -9.6% | +58.1% | +7.6% | +12.0% | +3.5% | -32.9% | +25.2% | +14.7% | +231.4% | +18.2% | +19.9% | +17338.3% | +1146.5% | -26.1% | -50.0% | -100.3% | -115.6% | |
| Net Margin | 4.5% | 7.7% | 8.0% | 7.4% | 3.9% | 4.4% | 5.1% | 4.6% | 3.5% | 3.6% | 5.4% | 6.1% | 5.0% | 5.7% | 5.4% | 6.8% | 1.6% | 6.4% | 4.5% | 2.9% | 11.8% |
| — | +73.9% | +55.7% | +58.7% | +11.1% | +21.7% | -5.2% | -23.5% | -29.3% | -35.8% | +1.0% | -11.2% | +213.8% | -12.0% | +19.3% | +137.0% | -86.6% | -53.2% | -69.1% | -76.8% | -69.5% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.5% | 6.1% | 6.3% | 5.1% | 2.3% | 2.6% | 3.5% | 3.4% | 2.5% | 2.3% | 3.2% | 3.0% | 2.5% | 3.2% | 3.4% | 4.4% | 0.9% | 4.0% | 3.0% | 1.9% | 6.3% |
| — | +134.7% | +80.4% | +49.8% | -5.6% | +10.3% | +8.6% | +12.7% | -2.5% | -27.5% | -4.4% | -31.9% | +167.7% | -19.6% | +13.0% | +135.8% | -85.1% | -48.8% | -69.2% | -78.3% | -76.0% | |
| ROA | 8.7% | 3.8% | 4.0% | 3.4% | 1.6% | 1.8% | 2.3% | 2.3% | 1.7% | 1.5% | 2.2% | 2.2% | 1.8% | 2.3% | 2.3% | 3.0% | 0.6% | 2.7% | 2.0% | 1.3% | 4.3% |
| — | +111.7% | +72.9% | +49.4% | -2.3% | +16.1% | +3.9% | +3.3% | -8.5% | -32.1% | -1.9% | -26.5% | +180.7% | -16.8% | +12.8% | +130.6% | -85.1% | -47.6% | -67.7% | -76.8% | -74.5% | |
| ROIC | 18.0% | 8.2% | 9.1% | 6.9% | 2.6% | 3.7% | 4.6% | 5.5% | 3.7% | 2.5% | 3.6% | 2.9% | 2.4% | 3.9% | 3.8% | 4.1% | 0.9% | 3.1% | 2.6% | -0.0% | -0.1% |
| — | +117.9% | +96.6% | +26.8% | -30.4% | +48.5% | +27.4% | +87.3% | +52.3% | -36.0% | -3.9% | -28.4% | +167.8% | +27.1% | +45.3% | +19612.0% | +1094.3% | -30.8% | -51.6% | -100.3% | -111.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.06 | 0.06 | 0.05 | 0.05 | 0.05 | 0.06 | 0.05 | 0.04 | 0.04 | 0.03 | 0.04 | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 |
| — | +4.4% | +20.2% | +11.6% | +17.7% | +31.5% | +13.7% | +64.9% | +30.3% | +11.3% | +12.7% | -22.4% | +71.2% | +77.3% | +72.8% | +69.1% | -40.4% | -43.2% | -41.9% | -41.4% | -39.9% | |
| Debt / EBITDA | 0.31 | 0.58 | 0.63 | 0.74 | 1.67 | 1.23 | 1.00 | 1.03 | 1.16 | 1.25 | 0.93 | 1.00 | 1.34 | 0.94 | 1.15 | 1.19 | 2.06 | 0.58 | 0.75 | 23.49 | 67.58 |
| — | -52.9% | -37.3% | -28.0% | +44.4% | -1.2% | +7.7% | +2.6% | -13.9% | +32.6% | -19.7% | -15.5% | -34.7% | +63.6% | +53.1% | -94.9% | -97.0% | -29.7% | +14.5% | +3448.7% | +899.3% | |
| Current Ratio | 2.73 | 1.93 | 2.14 | 2.13 | 2.73 | 2.96 | 2.70 | 2.39 | 2.80 | 2.62 | 2.58 | 3.31 | 3.44 | 3.16 | 2.89 | 2.55 | 2.72 | 2.56 | 2.46 | 2.40 | 2.62 |
| — | -34.5% | -20.8% | -11.1% | -2.7% | +12.8% | +4.4% | -27.7% | -18.6% | -17.1% | -10.7% | +29.9% | +26.6% | +23.4% | +17.7% | +6.1% | +3.9% | +5.2% | +1.9% | +6.4% | +7.0% | |
| Quick Ratio | 2.73 | 1.93 | 2.14 | 2.13 | 2.73 | 2.96 | 2.70 | 2.39 | 2.80 | 2.62 | 2.58 | 3.31 | 3.44 | 3.16 | 2.89 | 2.55 | 2.72 | 2.56 | 2.46 | 2.40 | 2.62 |
| — | -34.5% | -20.8% | -11.1% | -2.7% | +12.8% | +4.4% | -27.7% | -18.6% | -17.1% | -10.7% | +29.9% | +26.6% | +23.4% | +17.7% | +6.1% | +3.9% | +5.2% | +1.9% | +6.4% | +7.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PGNY stock.
Progyny, Inc.'s current P/E is 31.1x. The average P/E over the last 4 quarters is 25.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Progyny, Inc.'s current operating margin is 6.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Progyny, Inc.'s business trajectory between earnings reports.